Clinical trials are a crucial part of the research undertaken at Melanoma Institute Australia. Coordinated from the Poche Centre in Wollstonecraft and conducted at locations throughout our network, these trials help us find better ways to prevent, diagnose and treat melanoma, as well as help improve the quality of life of melanoma patients.
All of MIA’s clinical trials follow a strict protocol approved by a Human Research Ethics Committee. This committee ensures that the rights, safety and wellbeing of participants are protected throughout the trial.
Patients – To read more about participating in Clinical Trials see here.
Clinicians – For information on referring patients to an MIA Clinical Trial see here.
Download our Clinical Trial brochure to find out more about clinical trials.
Current Clinical Trials
Please use the Stage tabs below to find a suitable clinical trial being run at MIA. Includes Melanoma and Non-Melanoma trials which are currently recruiting and trials that will open soon.
SONIB
For patients with BCC that cannot be removed by surgery or that has spread through the body.
Diagnosis: Non-Melanoma
Stage: I/II
Setting: Neoadjuvant
Status: Recruiting
Trial ID: NCT03534947
More info >
I-MAT
A randomised, placebo-controlled, phase II trial in patients with stage I-III Merkel cell carcinoma aiming to explore the efficacy of avelumab as adjuvant immunotherapy.
Diagnosis: Non-Melanoma
Stage: I/II/III
Setting: Adjuvant
Status: Recruiting
Trial ID: NCT04291885
More info >
MCC-Neo
The goal of this clinical trial is to test neoadjuvant dual immunotherapy in Merkel cell carcinoma with the aim to improve recurrence-free survival.
Diagnosis: Non-Melanoma
Stage: I /II/ III resectable
Setting: Neoadjuvant
Status: Recruitment pending
Trial ID: NCT06151236
More info >
SONIB
For patients with BCC that cannot be removed by surgery or that has spread through the body.
Diagnosis: Non-Melanoma
Stage: I/II
Setting: Neoadjuvant
Status: Recruiting
Trial ID: NCT03534947
More info >
I-MAT
A randomised, placebo-controlled, phase II trial in patients with stage I-III Merkel cell carcinoma aiming to explore the efficacy of avelumab as adjuvant immunotherapy.
Diagnosis: Non-Melanoma
Stage: I/II/III
Setting: Adjuvant
Status: Recruiting
Trial ID: NCT04291885
More info >
MelMartII
For patients with a primary invasive melanoma who have been recommended excision with a wide margin.
Diagnosis: Melanoma
Stage: II
Setting: Surgical
Status: Recruiting
Trial ID: NCT03860883
More info >
KeyVibe-10
To compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS). The primary hypothesis is that pembrolizumab/vibostolimab is superior to pembrolizumab with respect to RFS as assessed by the investigator in participants with high-risk resected Stage IIB, IIC, III and IV melanoma.
Diagnosis: Melanoma
Stage: II/III/IV resected
Setting: Adjuvant
Status: Recruiting
Trial ID: NCT05665595
More info >
Neo ReNi II
A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma. Neoadjuvant therapy is feasible in stage II melanoma, and the dual inhibition of the distinct LAG-3 and PD-1 checkpoint pathways with relatlimab and nivolumab has a synergistic effect in the tumour microenvironment leading to a pathological response after 2 doses of therapy.
Diagnosis: Melanoma
Stage: II resectable
Setting: Neoadjuvant
Status: Recruiting
Trial ID: NCT05418972
More info >
MSD V940-001
The purpose of this study is to learn if V940 which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if V940 with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.
Diagnosis: Melanoma
Stage: II / III /IV resected
Setting: Adjuvant
Status: Recruiting
Trial ID: NCT05933577
More info >
Regeneron 2055
A trial to see if the combination of Fianlimab with Cemiplimab works better than Pembrolizumab for preventing or delaying melanoma recurrence after it has been removed with surgery.
Diagnosis: Melanoma
Stage: II/ III /IV
Setting: Adjuvant
Status: Recruitment pending
Trial ID: NCT05608291
More info >
MCC-Neo
The goal of this clinical trial is to test neoadjuvant dual immunotherapy in Merkel cell carcinoma with the aim to improve recurrence-free survival.
Diagnosis: Non-Melanoma
Stage: I /II/ III resectable
Setting: Neoadjuvant
Status: Recruitment pending
Trial ID: NCT06151236
More info >
I-MAT
A randomised, placebo-controlled, phase II trial in patients with stage I-III Merkel cell carcinoma aiming to explore the efficacy of avelumab as adjuvant immunotherapy.
Diagnosis: Non-Melanoma
Stage: I/II/III
Setting: Adjuvant
Status: Recruiting
Trial ID: NCT04291885
More info >
Keymaker-02C
To evaluate the safety and efficacy of investigational treatment arms in participants with Stage III melanoma who are candidates for neoadjuvant therapy to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available.
Diagnosis: Melanoma
Stage: III Resectable
Setting: Neoadjuvant
Status: Recruitment paused
Trial ID: NCT04303169
More info >
Keymaker-02B
To evaluate the safety and efficacy of investigational treatment arms in participants with 1L advanced melanoma and to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/pembrolizumab monotherapy.
Diagnosis: Melanoma
Stage: III/IV Unresectable
Setting: Metastatic (first line)
Status: Recruiting
Trial ID: NCT04305054
More info >
MORPHEUS
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)
Diagnosis: Melanoma
Stage: III Resectable
Setting: Neoadjuvant
Status: Recruitment paused
Trial ID: NCT05116202
More info >
BMS CA027-002
A Phase 1/2 Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Diagnosis: Melanoma
Stage: III/IV Unresectable
Setting: Metastatic (immunotherapy relapse)
Status: Recruitment paused
Trial ID: NCT03400332
More info >
KINNATE
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Diagnosis: Melanoma and other solid tumours
Stage: III/IV Unresectable
Setting: Metastatic (immunotherapy relapse)
Status: Recruitment paused
Trial ID: NCT04913285
More info >
KeyVibe-10
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma.
Diagnosis: Melanoma
Stage: II /III /IV resected
Setting: Adjuvant
Status: Recruiting
Trial ID: NCT05665595
More info >
Moderna mRNA-2752
A clinical study to assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.
Diagnosis: Melanoma
Stage: III/IV unresectable
Setting: Metastatic (immunotherapy relapse)
Status: Recruiting
Trial ID: NCT03739931
More info >
MSD V940-001
The purpose of this study is to learn if V940 which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if V940 with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.
Diagnosis: Melanoma
Stage: II / III /IV resected
Setting: Adjuvant
Status: Recruiting
Trial ID: NCT05933577
More info >
Moderna mRNA-4359
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Diagnosis: Melanoma
Stage: III/IV unresectable
Setting: Metastatic (immunotherapy relapse)
Status: Recruiting
Trial ID: NCTNCT05533697
More info >
RELATIVITY-127
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma.
Diagnosis: Melanoma
Stage: III/IV unresectable
Setting: Metastatic (first line)
Status: Recruiting
Trial ID: NCT05625399
More info >
Immunocore PRAME
IMC-F106C is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-F106C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.
Diagnosis: Melanoma
Stage: III / IV unresectable
Setting: Metastatic (immunotherapy relapse)
Status: Recruitment pending
Trial ID: NCT04262466
More info >
Immunocore TEBE-AM
To evaluate the efficacy and safety of tebentafusp-based regimens tebentafusp monotherapy and in combination with anti-PD1) vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care (SoC), best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma.
Diagnosis: Melanoma
Stage: III / IV unresectable
Setting: Metastatic (immunotherapy relapse)
Status: Recruiting
Trial ID: NNCT05549297
More info >
MatchMel
This is a patient oriented translational research project aiming to improve clinical outcomes for patients with BRAF and NRAS wild-type unresectable Stage III or Stage IV metastatic melanoma who have progressed on, or are unable to receive standard therapy (in general, immunotherapy). Consecutive patients seen at three major clinics and fitting the broad eligibility criteria will be invited to participate.
Diagnosis: Melanoma
Stage: III/IV Unresectable
Setting: Metastatic (immunotherapy relapse)
Status: Recruitment paused
Trial ID: NCT02645149
More info >
IoBio 032
This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab as neoadjuvant and adjuvant treatment. This proof-of-concept trial will include patients with resectable tumors in at least 2 indications.
Diagnosis: Melanoma
Stage: III Resectable
Setting: Neoadjuvant
Status: Recruitment pending
Trial ID: NCT05280314
More info >
Regeneron C-POST
This is a patient oriented translational research project aiming to improve clinical outcomes for patients with BRAF and NRAS wild-type unresectable Stage III or Stage IV metastatic melanoma who have progressed on, or are unable to receive standard therapy (in general, immunotherapy). Consecutive patients seen at three major clinics and fitting the broad eligibility criteria will be invited to participate.
Diagnosis: Non-Melanoma
Stage: High risk Stage III /IV
Setting: Adjuvant
Status: Recruitment pending
Trial ID: NCT03969004
More info >
Regeneron 2055
A trial to see if the combination of Fianlimab with Cemiplimab works better than Pembrolizumab for preventing or delaying melanoma recurrence after it has been removed with surgery.
Diagnosis: Melanoma
Stage: II/ III /IV
Setting: Adjuvant
Status: Recruitment pending
Trial ID: NCT05608291
More info >
Regeneron 22058
Diagnosis: Melanoma
Stage: III
Setting: Neoadjuvant
Status: Recruitment pending
Trial ID: Pending
More info >
MCC-Neo
The goal of this clinical trial is to test neoadjuvant dual immunotherapy in Merkel cell carcinoma with the aim to improve recurrence-free survival.
Diagnosis: Non-Melanoma
Stage: I /II/ III resectable
Setting: Neoadjuvant
Status: Recruitment pending
Trial ID: NCT06151236
More info >
ABC-X
A phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with asymptomatic, untreated melanoma brain metastases.
Diagnosis: Melanoma
Stage: IV Brain metastases
Setting: Metastatic (first line)
Status: Recruiting
Trial ID: NCT03340129
More info on clinicaltrials.gov >
See our ABC-X Clinical Trial page >
Keymaker-02B
To evaluate the safety and efficacy of investigational treatment arms in participants with 1L advanced melanoma and to identify the investigational agent(s) that when used in combination, are superior to the current treatment options/pembrolizumab monotherapy.
Diagnosis: Melanoma
Stage: III/IV
Setting: Metastatic
Status: Recruiting
Trial ID: NCT04305054
More info >
BMS CA027-002
A Phase 1/2 Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Diagnosis: Melanoma
Stage: III/IV Unresectable
Setting: Metastatic (immunotherapy relapse)
Status: Recruitment paused
Trial ID:NCT03400332
More info >
KINNATE
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Diagnosis: Melanoma and other solid tumours
Stage: III/IV Unresectable
Setting: Metastatic (immunotherapy relapse)
Status: Recruitment Paused
Trial ID:NCT04913285
More info >
KeyVibe-10
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma.
Diagnosis: Melanoma
Stage: II /III /IV resected
Setting: Adjuvant
Status: Recruiting
Trial ID: NCT05665595
More info >
MSD V940-001
The purpose of this study is to learn if V940 which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if V940 with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.
Diagnosis: Melanoma
Stage: II / III /IV resected
Setting: Adjuvant
Status: Recruiting
Trial ID: NCT05933577
More info >
Moderna mRNA-2752
A clinical study to assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.
Diagnosis: Melanoma
Stage: III/IV unresectable
Setting: Metastatic (immunotherapy relapse)
Status: Recruiting
Trial ID: NCT03739931
More info >
RELATIVITY-127
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma.
Diagnosis: Melanoma
Stage: III/IV unresectable
Setting: Metastatic (first line)
Status: Recruiting
Trial ID: NCT05625399
More info >
Moderna mRNA-4359
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Diagnosis: Melanoma
Stage: III/IV unresectable
Setting: Metastatic (immunotherapy relapse)
Status: Recruiting
Trial ID: NCTNCT05533697
More info >
Immunocore PRAME
IMC-F106C is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-F106C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.
Diagnosis: Melanoma
Stage: III / IV unresectable
Setting: Metastatic (immunotherapy relapse)
Status: Recruitment pending
Trial ID: NCT04262466
More info >
Immunocore TEBE-AM
To evaluate the efficacy and safety of tebentafusp-based regimens tebentafusp monotherapy and in combination with anti-PD1) vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care (SoC), best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma.
Diagnosis: Melanoma
Stage: III / IV unresectable
Setting: Metastatic (immunotherapy relapse)
Status: Recruiting
Trial ID: NNCT05549297
More info >
MatchMel
This is a patient oriented translational research project aiming to improve clinical outcomes for patients with BRAF and NRAS wild-type unresectable Stage III or Stage IV metastatic melanoma who have progressed on, or are unable to receive standard therapy (in general, immunotherapy). Consecutive patients seen at three major clinics and fitting the broad eligibility criteria will be invited to participate.
Diagnosis: Melanoma
Stage: III/IV Unresectable
Setting: Metastatic (immunotherapy relapse)
Status: Recruitment paused
Trial ID: NCT02645149
More info >
Regeneron C-POST
This is a patient oriented translational research project aiming to improve clinical outcomes for patients with BRAF and NRAS wild-type unresectable Stage III or Stage IV metastatic melanoma who have progressed on, or are unable to receive standard therapy (in general, immunotherapy). Consecutive patients seen at three major clinics and fitting the broad eligibility criteria will be invited to participate.
Diagnosis: Non-Melanoma
Stage: High risk Stage III /IV
Setting: Adjuvant
Status: Recruitment pending
Trial ID: NCT03969004
More info >
Regeneron 2055
A trial to see if the combination of Fianlimab with Cemiplimab works better than Pembrolizumab for preventing or delaying melanoma recurrence after it has been removed with surgery.
Diagnosis: Melanoma
Stage: II/ III /IV
Setting: Adjuvant
Status: Recruitment pending
Trial ID: NCT05608291
More info >
Clinical Trial Types and Phases
Clinical Trial Types
The U.S. National Institutes of Health (NIH) classify clinical trials into five types as follows:
1. Treatment Trials– the most common type of trial involving testing experimental treatments such as new drug combinations or new approaches to surgery or radiotherapy.
2. Prevention Trials – test new ways to prevent disease and disease recurrence.
3. Screening Trials – test the most effective way to detect a disease.
4. Diagnostic Trials– conducted to find better ways to diagnose disease.
5. Quality of Life Trials (or Supportive Care Trials)– explore ways to improve the comfort and quality of life for people with a disease.
Clinical Trial phases
New treatments must go through three “phases” of trials before they can be considered for use;
- Phase 1 – Involves only a small number of participants where a range of dosage levels are tested and any side effects analysed.
- Phase 2 – Involves a larger group of participants where a more detailed evaluation of safety and effectiveness is conducted.
- Phase 3 – Involves a much larger group of participants where the experimental treatment is formally compared with the current standard treatment by randomly allocating each treatment across the test group.Random treatment allocation is necessary in Phase 3 trials to ensure the treatments can be compared without bias. Neither the patient nor the trial team can choose which treatment is received. If the trial involves a new drug it is possible that the patient and the trial team might not be told which treatment group you are in; this is known as blinding and is used to prevent bias. In some trials experimental treatments are compared with a placebo – an inactive pill, liquid or powder that has no treatment value. Patients are informed if the trial being considered is blinded or placebo controlled.